HBM Holdings (HKG:2142) said China's National Medical Products Administration approved the investigational new drug (IND) application for HBM7575, a drug candidate for the treatment of atopic dermatitis, according to a Monday Hong Kong bourse filing.
HBM7575, also known as SKB575, is a long-acting bispecific antibody targeting thymic stromal lymphopoietin and an undisclosed antigen, designed to inhibit immune pathways linked to the skin condition, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments